Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Zhao, Lei ^a   He, Li Ru ^a   Xi, Mian ^a   Cai, Mu Yan ^a   Shen, Jing Xian ^a   Li, Qiao Qiao ^a   Liao, Yi Ji ^a   Qian, Dong ^a   Feng, Zi Zhen ^a   Zeng, Yi Xin ^a   Xie, Dan ^a   Liu, Meng Zhong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

EGFR; Esophageal squamous carcinoma cell; IGFBP 3; Nimotuzumab; Radiosensitivity

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NIMOTUZUMAB; SHORT HAIRPIN RNA; SOMATOMEDIN BINDING PROTEIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL GROWTH; CELL STRAIN; CELL STRAIN KYSE30; CELL STRAIN TE 1; CHEMORADIOTHERAPY; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GROWTH REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN RNA BINDING; RADIATION RESPONSE; RADIOSENSITIVITY; RNA INTERFERENCE; SINGLE DRUG DOSE; TUMOR XENOGRAFT; UPREGULATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; UP-REGULATION;

EID: 84870664853     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-249     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20. 10.1056/NEJMoa055531, 16822992.
3. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092. 10.1200/JCO.2007.12.9593, 18309943.
4. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, Lagarde N, Volant A. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005, 93:107-115. 10.1038/sj.bjc.6602625, 2361490, 15986037.
5. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, Geradts J, Javle M, Brattain M. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004, 8:448-453. 10.1016/j.gassur.2004.01.006, 15120370.
6. Harari PM, Huang SM. Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?. Int J Radiat Oncol Biol Phys 2004, 58:976-983. 10.1016/j.ijrobp.2003.09.097, 14967459.
7. Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004, 58:966-971. 10.1016/j.ijrobp.2003.08.035, 14967457.
8. Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Majo J, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005, 74:101-108. 10.1016/j.radonc.2004.12.021, 15816107.
9. Baumann M, Krause M, Dikomey E, Dittmann K, Dorr W, Kasten-Pisula U, Rodemann HP. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 2007, 83:238-248. 10.1016/j.radonc.2007.04.006, 17502118.
10. Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 2005, 62:309-317. 10.1016/j.ijrobp.2004.09.047, 15890569.
11. Vordermark D, Kolbl O. Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93-05 protocol: in regard to souhami et al. (Int J radiat oncol biol phys 2004;60:853-860). Int J Radiat Oncol Biol Phys 2005, 62:296-297. author reply 297, 10.1016/j.ijrobp.2005.01.046, 15850943.
12. Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, Lopez-Requena A, Pupo A, Johansen RF, Sanchez O, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009, 69:5851-5859. 10.1158/0008-5472.CAN-08-4518, 19584289.
13. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 2002, 101:567-575. 10.1002/ijc.10647, 12237899.
14. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004, 22:1646-1654. 10.1200/JCO.2004.03.089, 15117987.
15. Ramos TC, Figueredo J, Catala M, Gonzalez S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006, 5:375-379. 10.4161/cbt.5.4.2522, 16575203.
16. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2005, 27:193-219.
17. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007, 29:697-735.
18. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernandez LE, Crombet T, Kerbel RS, Perez R. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 2011, 11:373-382. 10.4161/cbt.11.4.14097, 21150278.
19. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007, 120:781-787. 10.1002/ijc.22370, 17096332.
20. Zhao L, Li QQ, Zhang R, Xi M, Liao YJ, Qian D, He LR, Zeng YX, Xie D, Liu MZ. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin. Tumour Biol 2012, 33:1115-1123. 10.1007/s13277-012-0352-0, 22389159.
21. Hu ZY, Zhu XF, Zhong ZD, Sun J, Wang J, Yang D, Zeng YX. ApoG2, A novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer 2008, 123:2418-2429. 10.1002/ijc.23752, 18712728.
22. Feng Z, Xu S, Liu M, Zeng YX, Kang T. Chk1 Inhibitor Go6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett 2010, 297:190-197. 10.1016/j.canlet.2010.05.011, 20619533.
23. Natsuizaka M, Ohashi S, Wong GS, Ahmadi A, Kalman RA, Budo D, Klein-Szanto AJ, Herlyn M, Diehl JA, Nakagawa H. Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis 2010, 31:1344-1353. 10.1093/carcin/bgq108, 2915630, 20513670.
24. Huang Y, Li LZ, Zhang CZ, Yi C, Liu LL, Zhou X, Xie GB, Cai MY, Li Y, Yun JP. Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis. J Transl Med 2012, 10:106. 10.1186/1479-5876-10-106, 3476987, 22625427.
25. Yoshino K, Motoyama S, Koyota S, Shibuya K, Usami S, Maruyama K, Saito H, Minamiya Y, Sugiyama T, Ogawa J. IGFBP3 And BAG1 enhance radiation-induced apoptosis in squamous esophageal cancer cells. Biochem Biophys Res Commun 2011, 404:1070-1075. 10.1016/j.bbrc.2010.12.115, 21195059.
26. Takaoka M, Harada H, Andl CD, Oyama K, Naomoto Y, Dempsey KL, Klein-Szanto AJ, El-Deiry WS, Grimberg A, Nakagawa H. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 2004, 64:7711-7723. 10.1158/0008-5472.CAN-04-0715, 15520175.
27. Takaoka M, Smith CE, Mashiba MK, Okawa T, Andl CD, El-Deiry WS, Nakagawa H. EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. Am J Physiol Gastrointest Liver Physiol 2006, 290:G404-G416. 10.1152/ajpgi.00344.2005, 2996094, 16210470.
28. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003, 57:246-254. 10.1016/S0360-3016(03)00511-X, 12909240.
29. Das AK, Chen BP, Story MD, Sato M, Minna JD, Chen DJ, Nirodi CS. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res 2007, 67:5267-5274. 10.1158/0008-5472.CAN-07-0242, 17545606.
30. Diaz Miqueli A, Rolff J, Lemm M, Fichtner I, Perez R, Montero E. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer 2009, 100:950-958. 10.1038/sj.bjc.6604943, 2661790, 19293809.
31. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008, 98:749-755. 10.1038/sj.bjc.6604222, 2259177, 18253126.
32. Okamoto I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J 2010, 277:309-315. 10.1111/j.1742-4658.2009.07449.x, 19922468.
33. Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008, 16:216-227. 10.1016/j.str.2007.11.009, 18275813.
34. Pavelic J, Pavelic L, Karadza J, Krizanac S, Unesic J, Spaventi S, Pavelic K. Insulin-like growth factor family and combined antisense approach in therapy of lung carcinoma. Mol Med 2002, 8:149-157. 2039980, 12142546.
35. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000, 275:39174-39181. 10.1074/jbc.M908888199, 10998426.
36. Bhattacharyya N, Pechhold K, Shahjee H, Zappala G, Elbi C, Raaka B, Wiench M, Hong J, Rechler MM. Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J Biol Chem 2006, 281:24588-24601. 10.1074/jbc.M509463200, 16793770.
37. Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J Biol Chem 2005, 280:16942-16948. 10.1074/jbc.M412757200, 15731112.
38. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002, 99:860-868. 10.1002/ijc.10427, 12115489.